XML 33 R21.htm IDEA: XBRL DOCUMENT v3.20.2
Summary of Significant Accounting Policies and Other Information (Tables)
3 Months Ended
Mar. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedules of Concentration of Risk, by Risk Factor
The following table presents customers individually accounting for more than 10% of the Company’s net sales:
 
 
For the Three Months Ended March 31,
 
 
2020
 
2019
Customer A
 
15
%
 
17
%
Customer B
 
10
%
 
**

Customer C
 
14
%
 
**

The following table presents customers individually accounting for more than 10% of the Company’s accounts receivable:
 
 
As of March 31, 2020
 
As of December 31, 2019
Customer A
 
16
%
 
**

Customer B
 
17
%
 
**

Customer C
 
**

 
49
%
The following table presents suppliers individually accounting for more than 10% of the Company’s purchases:
 
 
For the Three Months Ended March 31,
 
 
2020
 
2019
Supplier A
 
11
%
 
16
%
Supplier B
 
**

 
12
%
**    Less than 10% of the total
Schedule of Inventory, Current
Inventories consist of the following:
(in thousands)

Inventories
 
As of March 31, 2020
 
As of December 31, 2019
Raw materials
 
$
105,750

 
$
90,677

Work in process
 
4,426

 
2,007

Finished goods
 
18,641

 
19,119

Total inventories
 
128,817

 
111,803

Inventory allowance
 
(3,217
)
 
(2,964
)
Inventories, net
 
$
125,600

 
$
108,839

Activity in the Company’s inventory allowance was as follows:
(in thousands)
 
For the Three Months Ended March 31,
Inventory Allowance
 
2020
 
2019
Balance at beginning of period
 
$
2,964

 
$
5,730

Charged to expense
 
526

 
314

Write-offs
 
(273
)
 
(235
)
Balance at end of period
 
$
3,217

 
$
5,809

Schedule of Other Accrued Liabilities
Other accrued liabilities consisted of the following:
(in thousands)

Other Accrued Liabilities
 
As of March 31, 2020
 
As of December 31, 2019
Accrued product warranty
 
$
14,027

 
$
17,142

Litigation reserves *
 
5,420

 
5,020

Contract liabilities
 
36,670

 
26,898

Accrued compensation and benefits
 
6,515

 
6,599

Operating lease liabilities
 
3,732

 
3,789

Accrued interest expense
 
1,759

 
1,087

Other
 
7,475

 
5,495

Total
 
$
75,598

 
$
66,030

*
As of March 31, 2020 and December 31, 2019, litigation reserves primarily consisted of reserves related to ongoing government investigations and the settlement of the Federal Derivative Litigation. The Company concluded that insurance recovery was probable related to $2.2 million and $1.9 million of the litigation reserves as of March 31, 2020 and December 31, 2019, respectively, and recognized full recovery of the settlement amounts in Prepaid expenses and other current assets. See Note 9. Commitments and Contingencies for additional information.
Schedule of Accrued Product Warranty
Accrued product warranty activities are presented below:
(in thousands)
 
For the Three Months Ended March 31,
Accrued Product Warranty
 
2020
 
2019
Balance at beginning of period
 
$
25,501

 
$
23,101

Current year provision
 
2,325

 
1,467

Changes in estimates for preexisting warranties *
 
661

 
2,730

Payments made during the period
 
(3,926
)
 
(1,579
)
Balance at end of period
 
24,561

 
25,719

Less: Current portion
 
14,027

 
18,062

Noncurrent accrued product warranty
 
$
10,534

 
$
7,657

*
Change in estimates for preexisting warranties reflect changes in the Company’s estimate of warranty costs for products sold in prior periods. Such adjustments typically occur when claims experience deviates from historic and expected trends. The Company’s warranty liability is generally affected by failure rates, repair costs and the timing of failures. Future events and circumstances related to these factors could materially change the estimates and require adjustments to the warranty liability. In addition, new product launches require a greater use of judgment in developing estimates until historical experience becomes available. In the first quarter of 2020 and 2019, the Company recorded charges for changes in estimates of preexisting warranties of $0.7 million, or $0.03 per diluted share, and $2.7 million, or $0.12 per diluted share, respectively.